Form 4: Silence Therapeutics Director Increases Stake Through Significant ADS Purchases

Richard Ian Griffiths, a Director and 10% owner of Silence Therapeutics plc, acquired additional American Depositary Shares on July 21 and 22, 2025, increasing his indirect beneficial ownership.

Summary

• Richard Ian Griffiths, a Director and 10% owner of Silence Therapeutics plc (SLN), reported transactions on July 21 and 22, 2025.
• On July 21, 2025, Mr. Griffiths acquired 22,435 American Depositary Shares (ADS) at a price of $6.04 per ADS.
• These 22,435 ADSs are convertible into 67,305 ordinary shares (each ADS converts into three ordinary shares).
• Following this transaction, his indirect beneficial ownership increased to 11,781,093 ordinary shares.
• On July 22, 2025, an additional 2,910 American Depositary Shares were acquired at a price of $6.09 per ADS.
• These 2,910 ADSs are convertible into 8,730 ordinary shares.
• After both transactions, Mr. Griffiths' indirect beneficial ownership stands at 11,784,003 ordinary shares.
• The securities are held by Cream Capital Limited, where Mr. Griffiths serves as a director and controlling shareholder, disclaiming beneficial ownership except for his proportionate pecuniary interest.

Sentiment

Score: 8

Explanation: The acquisition of additional shares by a director and significant owner indicates strong confidence in the company's future prospects, which is generally a positive signal for investors.

Positives

• The acquisition of additional shares by a Director and 10% owner signals strong insider confidence in the company's future prospects.
• The increase in beneficial ownership by a key insider may be viewed positively by investors, indicating belief in the company's valuation and strategic direction.

Future Outlook

The filing is a transactional report and does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

This filing reports an insider transaction, which is a routine disclosure in the financial industry. While not directly related to broader industry trends, significant insider buying can sometimes reflect a positive outlook within a specific sector or company, irrespective of general market conditions.

Related Party Transactions

• The acquisition of American Depositary Shares by Richard Ian Griffiths, a Director and 10% owner, constitutes a related party transaction.
• The securities are held indirectly by Cream Capital Limited, where Mr. Griffiths is a director and controlling shareholder, indicating a related party relationship.

Stakeholder Impact

• Shareholders may interpret the insider buying as a positive signal of management confidence in the company's future, potentially influencing investment decisions.

Key Dates

Recommendation

The acquisition of additional shares by a director and 10% owner, Richard Ian Griffiths, signals strong insider confidence in Silence Therapeutics plc's future performance, which is typically viewed as a positive indicator for investors.

Keywords

Silence Therapeutics, SLN, Insider Trading, Director Purchase, ADS, Ordinary Shares, Stock Acquisition, Form 4, Beneficial Ownership